The primary objective of the current study is to assess cancer patient perceived barriers to adherence to oral cancer medications. The results of this survey will aid clinicians in identifying targeted priorities in future programs aimed at improving adherence in patients taking oral cancer medications.

The purpose of this study is to test the safety of the two study drugs, venetoclax and selinexor, and to find the highest dose of venetoclax and selinexor that can be given safely when it is combined with chemotherapy drugs (cytarabine or cytarabine and fludarabine). This study tests different doses of venetoclax and selinexor to see which dose is safer in children with leukemia.

Cancer caregivers experience high levels of stress related to the caregiving role, particularly for rural caregivers. The purpose of this study is to assess the acceptability and preliminary effect of enCompass Carolina, a social support program for caregivers of rural-dwelling patients with cancer.

To determine in a randomized manner whether the addition of levocarnitine prophylaxis to asparaginase-containing regimens will decrease the incidence of conjugated hyperbilirubinemia (>3 mg/dL) during ALL induction therapy in adolescents and young adults (AYAs, age 15-39 years).

The expected outcome of this proposal is a novel care pathway delivered by pharmacists to improve side effects during oral chemotherapy for patients, a known barrier to adherence, and ultimately to prevent progression and early mortality. Our long-term goal for P3OC is to develop and test new dashboard features to optimize pharmacy care, meet future needs for value-based payment models, and improve patient outcomes.

To find out if the addition of 2 blocks of inotuzumab ozogamicin to the standard chemotherapy regimen will improve outcomes in children and young adults with High-Risk (HR) B-cell acute lymphoblastic leukemia (B-ALL).

The main purpose of this clinical research study is to assess the safety, tolerability, efficacy (the ability of the study drug to produce the desired anti cancer effect), PK] and PD of GHF009X2101 the study drug in patients with relapsed or refractory hematologic malignancies including AML, CLL, SLL or other lymphomas [including other leukemia].

The primary endpoints are to determine the recommended phase 2 dose (RP2D) of SNDX-5613 administered in combination with chemotherapy in patients with relapsed or refractory KMT2A-rearranged (KMT2A-R) acute lymphoblastic leukemia (ALL), and to estimate the minimal residual disease (MRD) negative remission rate of patients with R/R infant KMT2A-R ALL treated with SNDX-5613 in combination with chemotherapy. Secondary endpoints include characterizing the pharmacokinetics (PK) of SNDX-5613 administered with chemotherapy in patients with R/R infant KMT2A-R ALL, estimating the 18-month event-free survival (EFS) of patients with R/R infant KMT2A-R ALL treated with SNDX5613 in combination with chemotherapy, estimating 18-month overall survival (OS) of patients with R/R infant KMT2A-R ALL treated with SNDX5613 in combination with hemotherapy, and characterizing the tolerability of SNDX-5613 given as monotherapy in patients with R/R infant KMT2A-R ALL. The exploratory endpoint is to assess the biologic activity of SNDX-5613 administered with chemotherapy in patients with R/RKMT2A-R ALL.